Study Supports Palliative Care for Cancer Patients

Kavita Dharmarajan, MD, M.Sc

Kavita Dharmarajan, MD, M.Sc

Advanced-stage cancer patients who received palliative care required shorter durations of radiation treatment and had shorter hospital stays, according to a recent study at the Icahn School of Medicine at Mount Sinai.

“Radiation therapy is very effective at relieving pain, but the standard two weeks of treatment may be too long or burdensome for some patients, given the state of their illnesses,” says the study’s senior author, Kavita Dharmarajan, MD, M.Sc, Assistant Professor of Radiation Oncology, and Geriatrics and Palliative Medicine, at the Icahn School of Medicine at Mount Sinai. “We showed that shorter course treatments can be equally, if not more, effective, especially when combined with other forms of therapy that put patients first, and not the tumor.” Read more

A Pioneer in Multiple Myeloma Joins Mount Sinai

Bart Barlogie, MD, PhD

Bart Barlogie, MD, PhD

Bart Barlogie, MD, PhD, a world-renowned physician who introduced the first curative therapy for multiple myeloma, a multidrug regimen known as Total Therapy, recently joined The Tisch Cancer Institute as Director of Research in the Multiple Myeloma Program.

Dr. Barlogie will work with the program’s leader, Sundar Jagannath, MD, Professor of Medicine (Hematology and Medical Oncology), to develop new therapies to treat the disease, which is characterized by cancerous plasma cells that form in the bone marrow and crowd out normal, blood-forming cells. Their collaboration helps make Mount Sinai the nation’s premier myeloma program. About 26,850 new cases of the disease occur in the United States each year, according to the American Cancer Society. Read more

The Tisch Cancer Institute Receives National Designation

The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai has been named a National Cancer Institute (NCI)-designated Cancer Center, an honor reserved for an elite group of U.S. institutions committed to researching and treating cancer.

In conjunction with the NCI designation, The Tisch Cancer Institute received a five-year, $8.5 million grant to support research and the recruitment of top physicians and scientists. More than 50 of the nation’s leading cancer researchers have joined The Tisch Cancer Institute since it was established in 2008. Read more

Celebrating Cancer Survivors

Singer and musician Johannes Schwaiger—who lost his voice after radiation treatment for throat and neck cancer but regained it following treatment at Mount Sinai Beth Israel—entertained more than 200 guests at Mount Sinai’s annual National Cancer Survivors Day® luncheon, held recently at Mount Sinai Beth Israel Phillips Ambulatory Care Center. Among the attendees were cancer survivors, their families and friends, and Mount Sinai faculty and staff. Charles L. Shapiro, MD, Professor of Medicine, Co-Director of the Dubin Breast Center at The Mount Sinai Hospital, Director of Translational Breast Cancer Research, and Director of Cancer Survivorship, Tisch Cancer Institute, delivered the keynote address. “More cancer survivors will experience cures, mainly due to screening, early detection, and improved treatments and supportive care,” Dr. Shapiro says. “Sometimes treatment causes long-term side effects that can affect survivors’ quality of life, so we need to prevent or treat them effectively.”

Multiple Myeloma Symposium Provides Clinical Insights

The Multiple Myeloma Research Foundation (MMRF) and Sundar Jagannath, MD, Director, Multiple Myeloma Program, The Tisch Cancer Institute, Mount Sinai Health System, teamed up recently to host a free patient education symposium at the Sheraton New York. Dr. Jagannath is a renowned researcher and clinician in the treatment of multiple myeloma, a relatively rare cancer of the bone marrow that results from abnormal growth of plasma cells. The MMRF, based in Norwalk, Connecticut, is the world’s No. 1 private funder of multiple myeloma research. The 200 attendees learned about managing the disease and today’s most promising treatment options from leading Mount Sinai clinicians. Participants included Ajai Chari, MD, Director of Clinical Research, Multiple Myeloma Program; and Hearn Jay Cho, MD, Assistant Professor of Medicine (Hematology and Medical Oncology), and Bethann Scarborough, MD, Assistant Professor of Medicine (Geriatrics and Palliative Medicine), at Icahn School of Medicine at Mount Sinai. Mount Sinai’s Multiple Myeloma Program is the largest of its kind in New York City.